Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Initial combination therapy resulted in significant improvements compared with monotherapy for changes in HbA1c (weighted mean difference [WMD] 0.43%
Combining incretin-based medicines could compound gastrointestinal effects, dehydration risk, and hypoglycemia risk when other glucose-lowering drugs are involved
Human pharmacokinetics, doseresponse, and mechanism validation remain limited
Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should discuss this with their prescriber as a precaution
WADA S0 prohibits use by competitive athletes
US$ 25.42
US$ 28.15
US$ 28.14
US$ 28.63
US$ 25.06
US$ 24.61
US$ 22.18
US$ 28.38
US$ 25.43
US$ 21.27
US$ 23.69
US$ 21.82
US$ 20.25
